Free Trial

Laboratory Co. of America (LH) Stock Forecast & Price Target

Laboratory Co. of America logo
$239.67 -0.50 (-0.21%)
(As of 11/22/2024 ET)

Laboratory Co. of America - Analysts' Recommendations and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Sell
0
Hold
4
Buy
11

Based on 15 Wall Street analysts who have issued ratings for Laboratory Co. of America in the last 12 months, the stock has a consensus rating of "Moderate Buy." Out of the 15 analysts, 4 have given a hold rating, 10 have given a buy rating, and 1 has given a strong buy rating for LH.

Consensus Price Target

$255.92
6.78% Upside
According to the 15 analysts' twelve-month price targets for Laboratory Co. of America, the average price target is $255.92. The highest price target for LH is $289.00, while the lowest price target for LH is $230.00. The average price target represents a forecasted upside of 6.78% from the current price of $239.67.
Get the Latest News and Ratings for LH and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Laboratory Co. of America and its competitors.

Sign Up

LH Analyst Ratings Over Time

TypeCurrent Forecast
11/24/23 to 11/23/24
1 Month Ago
10/25/23 to 10/24/24
3 Months Ago
8/26/23 to 8/25/24
1 Year Ago
11/24/22 to 11/24/23
Strong Buy
1 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
10 Buy rating(s)
10 Buy rating(s)
9 Buy rating(s)
8 Buy rating(s)
Hold
4 Hold rating(s)
4 Hold rating(s)
4 Hold rating(s)
2 Hold rating(s)
Sell
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
Consensus Price Target$255.92$251.85$247.42$243.67
Forecasted Upside6.78% Upside9.47% Upside7.16% Upside14.55% Upside
Consensus Rating
Moderate Buy
Moderate Buy
Moderate Buy
Moderate Buy

LH Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

LH Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

Laboratory Co. of America Stock vs. The Competition

TypeLaboratory Co. of AmericaMedical CompaniesS&P 500
Consensus Rating Score
2.80
2.80
2.50
Consensus RatingModerate BuyModerate BuyModerate Buy
Predicted Upside6.78% Upside26,878.84% Upside7.66% Upside
News Sentiment Rating
Positive News

See Recent LH News
Neutral News
Positive News
DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
10/30/2024Hsbc Global Res
0 of 5 stars
M. Herholdt
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeHold ➝ Strong-Buy
10/30/2024HSBC
2 of 5 stars
 UpgradeHold ➝ Buy
10/28/2024Piper Sandler
2 of 5 stars
D. Westenberg
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost TargetNeutral ➝ Neutral$235.00 ➝ $240.00+6.14%
10/25/2024Barclays
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetEqual Weight ➝ Equal Weight$234.00 ➝ $249.00+8.69%
10/25/2024Robert W. Baird
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetOutperform ➝ Outperform$282.00 ➝ $289.00+25.61%
9/24/2024Evercore ISI
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetIn-Line ➝ In-Line$250.00 ➝ $240.00+8.83%
9/23/2024Jefferies Financial Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetBuy ➝ Buy$245.00 ➝ $265.00+18.65%
8/5/2024Bank of America
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetBuy ➝ Buy$240.00 ➝ $260.00+13.39%
8/2/2024UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetBuy ➝ Buy$260.00 ➝ $270.00+14.63%
8/2/2024Deutsche Bank Aktiengesellschaft
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetHold ➝ Hold$220.00 ➝ $230.00-2.35%
8/2/2024Truist Financial
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetBuy ➝ Buy$255.00 ➝ $275.00+18.79%
5/30/2024JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetOverweight ➝ Overweight$261.00 ➝ $243.00+25.49%
3/25/2024Argus
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 UpgradeHold ➝ Buy$250.00+17.23%
2/26/2024Leerink Partnrs
Subscribe to MarketBeat All Access for the recommendation accuracy rating
M. Cherny
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform
2/26/2024Leerink Partners
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageOutperform$260.00+18.63%
10/31/2023Mizuho
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetBuy ➝ Buy$257.00 ➝ $230.00+16.07%
8/14/2023Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetOverweight ➝ Overweight$290.00 ➝ $270.00+23.85%
8/3/2023Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetOverweight ➝ Overweight$285.00 ➝ $260.00+20.81%
8/2/2023Credit Suisse Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetOutperform ➝ Outperform$247.41 ➝ $231.00+8.14%
4/26/2023Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower Target$260.00 ➝ $235.00+6.14%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Saturday at 12:18 PM ET.


Should I Buy Laboratory Co. of America Stock? LH Pros and Cons Explained

These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Wednesday, November 20, 2024. Please send any questions or comments about these Laboratory Co. of America pros and cons to contact@marketbeat.com.

Laboratory Co. of America
Bull Case

green Wall Street bull icon

Here are some ways that investors could benefit from investing in Laboratory Co. of America Holdings:

  • The stock has recently been trading at approximately $246.22, reflecting a positive market sentiment and potential for growth.
  • Institutional investors own 95.94% of the company's stock, indicating strong confidence from large financial entities in the company's future performance.
  • Recent upgrades from multiple analysts, including a "strong-buy" rating from HSBC Global Research, suggest that experts see significant upside potential in the stock.
  • Laboratory Co. of America Holdings has seen a consistent increase in target prices from analysts, with the average target now at $255.92, which could indicate a favorable investment opportunity.
  • The company has demonstrated resilience and growth in the medical research sector, which is increasingly important in today's healthcare landscape.

Laboratory Co. of America
Bear Case

red Wall Street bear icon

Investors should be bearish about investing in Laboratory Co. of America Holdings for these reasons:

  • Despite positive ratings, the stock has a one-year low of $191.97, indicating potential volatility and risk for investors.
  • With a high percentage of institutional ownership, there may be less room for retail investors to influence stock price movements.
  • Recent acquisitions by various funds suggest that the stock may be nearing saturation in terms of institutional interest, which could limit future price appreciation.
  • The medical research sector can be highly competitive and subject to regulatory changes, which may impact the company's profitability.
  • Market fluctuations and economic uncertainties could pose risks to the stock's performance, making it a potentially unstable investment in the short term.

LH Forecast - Frequently Asked Questions

According to the research reports of 15 Wall Street equities research analysts, the average twelve-month stock price forecast for Laboratory Co. of America is $255.92, with a high forecast of $289.00 and a low forecast of $230.00.

15 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Laboratory Co. of America in the last twelve months. There are currently 4 hold ratings, 10 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" LH shares.

According to analysts, Laboratory Co. of America's stock has a predicted upside of 6.78% based on their 12-month stock forecasts.

Over the previous 90 days, Laboratory Co. of America's stock had 2 upgrades by analysts.

Laboratory Co. of America has been rated by research analysts at Barclays, Evercore ISI, Hsbc Global Res, HSBC, Jefferies Financial Group, Piper Sandler, and Robert W. Baird in the past 90 days.

Analysts like Laboratory Co. of America less than other "medical" companies. The consensus rating score for Laboratory Co. of America is 2.80 while the average consensus rating score for "medical" companies is 2.80. Learn more on how LH compares to other companies.


This page (NYSE:LH) was last updated on 11/23/2024 by MarketBeat.com Staff
From Our Partners